Search the Newsreel

Commonwealth of Pennsylvania Public School Empls Retrmt SYS Has $30.31 Million Stake in Pfizer Inc. $PFE

The Commonwealth of Pennsylvania Public School Employees’ Retirement System recently reduced its stake in Pfizer Inc. by 5% in the second quarter, selling 65,593 shares but still holding 1.26 million shares valued at approximately $30.31 million. Despite this reduction, institutional investors collectively own a …

Hennessy Advisors Inc. Acquires 63,013 Shares of Pfizer Inc. $PFE

Hennessy Advisors Inc. increased its stake in Pfizer Inc. by 27% in the second quarter, acquiring 63,013 additional shares and bringing its total holdings to 296,113 shares valued at approximately $7.13 million. Despite institutional investors owning 68.36% of Pfizer, analyst sentiment remains cautious with …

Notable trades: Netflix, Coca-Cola, Pfizer among notable names

Insider transactions were seen across major firms this week, including Netflix (NFLX [https://seekingalpha.com/symbol/NFLX]), Merck (MRK [https://seekingalpha.com/symbol/MRK]), and Pfizer (PFE [https://seekingalpha.com/symbol/PFE]). The following trades took place between August 10 and August 14. * Netflix (NFLX [https://seekingalpha.com/symbol/NFLX]) Chief Financial Officer Spencer Neumann sold 9,248 shares at …

Pfizer Inc. $PFE Stock Position Lifted by Park National Corp OH

Park National Corp OH significantly increased its stake in Pfizer Inc. by 332.1% in the second quarter, now holding 242,081 shares valued at approximately $5.8 million. Despite this, analysts maintain a "Hold" rating for Pfizer with a $28.28 price target, citing concerns over post-COVID …

Independent Financial Group LLC Purchases 57,994 Shares of Pfizer Inc. $PFE

Independent Financial Group LLC significantly increased its stake in Pfizer Inc. during the second quarter, buying 57,994 additional shares and bringing its total holding to 122,166 shares valued at $2.94 million. Institutional investors collectively own 68.36% of Pfizer, which recently reported strong quarterly earnings …

What Pfizer (PFE)'s EMA Lyme Vaccine Filing and Updated Outlook Means For Shareholders

Pfizer recently reported Q2 2026 results, showing a net loss but raising its full-year revenue guidance to US$60.5 billion–US$62.5 billion. Concurrently, the European Medicines Agency validated the Marketing Authorization Application for Pfizer and Valneva’s Lyme disease vaccine candidate, a step that could diversify Pfizer's …

Pfizer (PFE) Stock Looks Reasonable On Returns But Stretched On Earnings

Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Pfizer stock has delivered a roughly 28% decline over the past five years, yet recent gains and a mixed set of valuation checks …

New owner secures mystery tenant for Everett plant shelved by Pfizer

A California developer has purchased the unfinished $350 million biomanufacturing facility in Everett that Pfizer halted after acquiring Seagen in 2023. The new owner has also secured a tenant for the plant, though the tenant's identity remains undisclosed. This development provides a future for …

Pfizer CEO Caps Post-Earnings Insider Buying Spree With $1 Million Stock Purchase

Three Pfizer insiders executed transactions directly on the heels of the drugmaker’s second-quarter earnings report. Continue Reading

Pfizer’s Korean Paxlovid Study Signals Ongoing Value in High‑Risk COVID Market

Pfizer Inc. has completed a real-world study in Korea on Paxlovid, demonstrating its effectiveness in older adults within long-term care hospitals against severe COVID-19, mortality, and decline in daily function. This observational study, which compared Paxlovid users to non-users matched on various factors, supports …

Pfizer (PFE) reports $170.4M across 20 institutional holdings in 13F

Pfizer Inc. (PFE), acting as an institutional investment manager, filed a quarterly Form 13F holdings report. The report details 20 equity investment positions with a total value of $170.4 million. The filing was signed by Madelyn D. Purcell, Assistant General Counsel, and indicates that …

QRG Capital Management Inc. Acquires 49,804 Shares of Pfizer Inc. $PFE

QRG Capital Management Inc. increased its stake in Pfizer Inc. by 5.8% during the second quarter, acquiring 49,804 additional shares and bringing its total holdings to 902,308 shares valued at approximately $21.7 million. This comes as institutional investors collectively own 68.36% of Pfizer's stock. …

Pfizer Inc.: Konsensus der Analysten und Kursziel | 852009 | US7170811035

Pfizer and Valneva’s Lyme Disease Vaccine Candidate Marketing Authorization Application Validated by European Medicines Agency

Submission based on favorable efficacy and safety results from Phase 3 VALOR trial NEW YORK & LYON, France, August 14, 2026--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) today announced that the European Medicines Agency (EMA) has validated the …

How Pfizer’s Higher 2026 Guidance And LITFULO Trial Results At Pfizer (PFE) Have Changed Its Investment Story

In early August 2026, Pfizer Inc. reported second-quarter results showing revenue of US$15,034 million and a net loss of US$248 million, alongside US$4.30 billion in non-cash intangible asset impairments and a modest increase in full-year 2026 revenue guidance to US$60.50–US$62.50 billion. A key offsetting …

Pfizer CEO Buys $1 Million of Stock

This article first appeared on GuruFocus. Pfizer Inc. (PFE, Financials) The pharmaceutical giant earned a new vote of confidence from its top executive. Albert Bourla bought about $1 million worth of company stock. Bourla purchased 38,000 shares at $26.34 apiece, which increased his ownership …

Pfizer-Aktie Prognose: Sollten Sie jetzt kaufen?

Pfizer, Inc. Stock 12‑Month Price Target Cut to $28.28, Implies 7% Upside

The average 12-month price target for Pfizer, Inc. (PFE) stock has been reduced from $28.47 to $28.28 by 24 analysts, with forecasts ranging from $25 to $35.75. This updated target implies a potential upside of approximately 7% from the Aug. 12 closing price. The …

5 Insightful Analyst Questions From Pfizer’s Q2 Earnings Call

5 Insightful Analyst Questions From Pfizer's Q2 Earnings Call Pfizer's second quarter results reflected stability in its core business despite ongoing challenges in COVID-related product demand. The company's performance was shaped by strong execution in its non-COVID portfolio, with management highlighting robust revenue contributions …

Insulet hires Pfizer alum Joan Campion to lead external comms

Insulet, a medical device company, has appointed Joan Campion, formerly of Pfizer, as its new VP of external communications for corporate affairs. This new role is part of a broader effort by Insulet to enhance its communications function under Chief Corporate Affairs Officer Cristal …

Listening to the Hemophilia Community: Pfizer Survey Reveals Unspoken Compromises

A Pfizer survey conducted with The Harris Poll found that many hemophilia patients and caregivers, while reporting satisfaction with current treatments, still experience significant burdens and make unspoken compromises in their daily lives. The survey, involving over 1,000 participants across four countries, highlighted challenges …

Will Pfizer's Non-COVID Portfolio Drive Its Next Phase of Growth?

Pfizer is shifting its growth strategy away from COVID-19 products, focusing instead on its non-COVID portfolio through new product launches, strategic acquisitions, and pipeline development in oncology and obesity. The company's recent Q2 2026 results showed significant operational growth in non-COVID revenues, leading to …

Formation Bio taps Biogen, Pfizer alum to tackle R&D’s ‘boring middle’

Formation Bio has appointed Dr. Michael Ehlers, a former Biogen and Pfizer executive, as its new chief scientific officer and head of R&D. The company aims to leverage AI to optimize the often-overlooked "boring middle" of drug development, such as trial enrollment and site …

Pfizer (PFE) Agreed To A $44 Million Chantix Settlement

Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Pfizer (NYSE:PFE) agreed to a US$44 million class action settlement related to its smoking cessation drug Chantix, addressing claims tied to product safety disclosures. …

Pfizer (PFE) Agrees To $44 Million Class Action Settlement

Pfizer has agreed to a US$44 million class action settlement concerning its Chantix smoking cessation drug, addressing allegations of undisclosed carcinogenic nitrosamines. This settlement is considered small relative to Pfizer's substantial revenue, fitting within existing regulatory and product liability risk frameworks rather than introducing …

Pfizer Inc. stock underperforms Tuesday when compared to competitors

Pfizer Inc. (PFE) stock fell by 1.59% on Tuesday, closing at $26.62, and underperformed the broader market, as the S&P 500 Index and Dow Jones Industrial Average also saw declines. This drop ended a seven-day winning streak for the stock. The article highlights Pfizer's …

Pfizer vs AbbVie: What's the Better Dividend Stock for Investors in 2026?

This article compares AbbVie (ABBV) and Pfizer (PFE) as dividend stock options for investors in 2026. While AbbVie offers solid financials, strong free cash flow, and consistent dividend growth despite a lower current yield, Pfizer provides a much higher immediate yield but comes with …

Pfizer (PFE) Q2 2026 Earnings Call Transcript

Image source: The Motley Fool. DATE Tuesday, Aug. 4, 2026 at 11:00 a.m. ET CALL PARTICIPANTS Chairman and Chief Executive Officer - Albert Bourla Chief Financial Officer - David Denton Incoming Interim Chief Financial Officer and Executive Vice President - Cecile Guegan Chief Scientific …

Pfizer Inc. (PFE) vs. BioNTech SE (BNTX): Which Pharma Giant Is Better Positioned for the Post-COVID Era?

Pfizer Inc. (NYSE:PFE) and BioNTech SE (NASDAQ:BNTX), two companies forever linked by their historic COVID-19 vaccine partnership, reported Q2 2026 earnings alongside major strategic announcements. While the European Commission authorized their updated XFG-adapted COVID-19 vaccine on July 29, the two partners are traveling down …

KMG Fiduciary Partners LLC Acquires 39,875 Shares of Pfizer Inc. $PFE

KMG Fiduciary Partners LLC increased its stake in Pfizer Inc. by 26.4% in the second quarter, purchasing 39,875 shares to bring its total holdings to 190,888 shares valued at approximately $4.6 million. Despite this increased institutional interest, analyst sentiment remains cautious with an average …

Pfizer, Inc. (PFE) Stock Price, News, Quote & History

This page provides a comprehensive overview of Pfizer, Inc. (PFE) stock information, including its real-time price, recent news, and performance data. The stock closed at $27.05, up 1.08%, with overnight trading activity showing a slight dip to $26.97. Recent news highlights Pfizer's Q2 earnings, …

Pfizer's Earnings Have Declined 58% This Year. Is a Dividend Cut Around the Corner?

Pfizer's earnings have fallen 58% this year, largely due to impairment charges, raising concerns about its dividend sustainability. While net income is down, the company's free cash flow of $11 billion over the past four quarters exceeds its dividend payments of $9.8 billion, suggesting …

Pfizer Inc (PFE-N) Press Releases

This page aggregates recent news and analyst opinions concerning Pfizer Inc. (PFE-N). It covers topics such as Pfizer's earnings, dividend outlook, advancements in COVID-19 booster strategies with BioNTech, and development of new weight-loss drugs. Various financial analysts and news outlets provide insights into the …